CKDXFOTCBiological Products, (No Diagnostic Substances)Fiscal year ends June 30Also trades as CYVNY

Opthea Ltd

Financials through fiscal 2025, year ended Jun 30, 2025Last filing: 20-F on Sep 15, 2025

$0.01+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Earnings

Quarterly results announced on Form 8-K, Item 2.02

Quarter	Reported	Time	Revenue	EPS (GAAP)	EPS (adjusted)
Q4 FY2024 Ended Jun 30, 2024	Aug 30, 2024	Before market open	–	–	–
Q4 FY2022 Ended Jun 30, 2022	Aug 30, 2022	Before market open	–	–	–

Press releases

Announcements Opthea filed with the SEC

Nov 20, 2025, 4:02 PM ET
Opthea announces voluntary delisting from Nasdaq takes effect
EX-99.1 to Form 6-K
Nov 12, 2025, 8:30 AM ET
Results of Annual General Meeting
EX-99.1 to Form 6-K
Oct 31, 2025, 9:28 AM ET
Agreed settlement with DFA investors
EX-99.1 to Form 6-K
Oct 30, 2025, 8:00 AM ET
Opthea streamlines global operations and
EX-99.1 to Form 6-K
Oct 27, 2025, 6:01 AM ET
ASX, Nasdaq and Media Release
EX-99.1 to Form 6-K
Oct 10, 2025, 6:01 AM ET
2025 Notice of Annual General Meeting and Explanatory Notes OPTHEA
EX-99.1 to Form 6-K
Oct 6, 2025, 6:01 AM ET
ASX, Nasdaq and Media Release
EX-99.1 to Form 6-K
Sep 15, 2025, 6:01 AM ET
2024 2025 Corporate Governance Statement Rules 4.7.3 and 4.10.3
EX-99.2 to Form 6-K
Aug 19, 2025, 7:32 PM ET
CORPORATE UPDATE INVESTOR CALL – 20 August 2025 Dr Jeremy Levin – Chairman of the Board Fred Guerard – Chief Executive Officer Tom Reilly – Chief Financial Officer
EX-99.1 to Form 6-K
Aug 19, 2025, 6:30 AM ET
ASX, Nasdaq and Media Release
EX-99.1 to Form 6-K
Aug 19, 2025, 6:01 AM ET
ASX, Nasdaq and Media Release
EX-99.1 to Form 6-K
Jun 2, 2025, 6:05 AM ET
ASX, Nasdaq and Media Release
EX-99.1 to Form 6-K
Apr 10, 2025, 6:05 AM ET
ASX, Nasdaq and Media Release
EX-99.1 to Form 6-K
Mar 31, 2025, 6:07 AM ET
ASX, Nasdaq and Media Release
EX-99.1 to Form 6-K
Mar 24, 2025, 6:06 AM ET
ASX, Nasdaq and Media Release
EX-99.1 to Form 6-K
Mar 3, 2025, 6:02 AM ET
ASX, Nasdaq and Media Release
EX-99.1 to Form 6-K
Feb 28, 2025, 6:03 AM ET
ASX, Nasdaq and Media Release
EX-99.1 to Form 6-K
Feb 28, 2025, 6:03 AM ET
This page has been left blank intentionally. iv Opthea 2025 Half‑Year Repor t
EX-99.2 to Form 6-K
Feb 26, 2025, 6:01 AM ET
ASX, Nasdaq and Media Release
EX-99.1 to Form 6-K
Feb 18, 2025, 6:06 AM ET
ASX, Nasdaq and Media Release
EX-99.1 to Form 6-K
Feb 7, 2025, 6:04 AM ET
ASX, Nasdaq and Media Release
EX-99.1 to Form 6-K
Feb 6, 2025, 6:02 AM ET
ASX, Nasdaq and Media Release
EX-99.1 to Form 6-K
Jan 28, 2025, 1:30 PM ET
Transforming Patient Outcomes with Superior Vision Gains Investor Event | New York City | January 28, 2025 NASDAQ (OPT); ASX (OPT.AX) Exhibit 99.1
EX-99.1 to Form 6-K
Jan 13, 2025, 6:05 AM ET
Transforming Patient Outcomes with Superior Vision Gains Corporate Overview | January 2025 NASDAQ (OPT); ASX (OPT.AX) Exhibit 99.1
EX-99.1 to Form 6-K
Jan 8, 2025, 6:02 AM ET
ASX, Nasdaq and Media Release
EX-99.1 to Form 6-K
Jan 7, 2025, 6:02 AM ET
ASX, Nasdaq and Media Release
EX-99.1 to Form 6-K
Dec 19, 2024, 6:02 AM ET
ASX, Nasdaq and Media Release
EX-99.1 to Form 6-K
Nov 26, 2024, 6:02 AM ET
ASX, Nasdaq and Media Release
EX-99.1 to Form 6-K
Nov 25, 2024, 6:02 AM ET
ASX, Nasdaq and Media Release
EX-99.1 to Form 6-K
Nov 19, 2024, 6:03 AM ET
Transforming Patient Outcomes with Superior Vision Gains Corporate Overview | November 2024 NASDAQ (OPT); ASX (OPT.AX) Exhibit 99.1
EX-99.1 to Form 6-K
Nov 15, 2024, 6:02 AM ET
ASX, Nasdaq and Media Release
EX-99.1 to Form 6-K
Nov 15, 2024, 6:02 AM ET
ASX, Nasdaq and Media Release
EX-99.2 to Form 6-K
Nov 15, 2024, 6:02 AM ET
ASX, Nasdaq and Media Release
EX-99.3 to Form 6-K
Nov 12, 2024, 6:03 AM ET
ASX, Nasdaq and Media Release
EX-99.1 to Form 6-K
Nov 4, 2024, 6:02 AM ET
ASX, Nasdaq and Media Release
EX-99.1 to Form 6-K
Oct 31, 2024, 9:33 PM ET
ASX, Nasdaq and Media Release
EX-99.1 to Form 6-K
Oct 28, 2024, 6:03 AM ET
Transforming Patient Outcomes with Superior Vision Gains Corporate Overview | October 2024 NASDAQ (OPT); ASX (OPT.AX) Exhibit 99.1
EX-99.1 to Form 6-K
Oct 16, 2024, 6:03 AM ET
2023 – 2024 Notice of Meeting and Explanatory Notes A transformative treatment for wet AMD is in (SIGHT) opthea
EX-99.1 to Form 6-K
Oct 16, 2024, 6:01 AM ET
ASX, Nasdaq and Media Release
EX-99.1 to Form 6-K
Oct 10, 2024, 6:02 AM ET
ASX, Nasdaq and Media Release
EX-99.1 to Form 6-K

Where these numbers come from

Parsed from the XBRL in Opthea's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CKDXF.

Company	Revenue	Growth
CKDXF	$25.00K	-80.0%
ARGX	–	–
ENTX	$0	-100.0%
RADX	–	–
GPLB	–	–
AGTX	–	–

Company

Exchange: OTC
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: June 30
Employees: 4
Auditor: Deloitte Touche Tohmatsu
SEC CIK: 1815620

Advertisement
300 × 250